TRVN:OTCMKTS
Trevena Inc
0,066 $
0,00%
(0,00) 1 d.
12. okt., 14:57:26 GMT-4 · USD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: TRVN…
Tirgus kapitalizācija
57,01 tūkst.
Vid. apjoms
210,00
Apjoms
9,00
Augstākā 52 ned.
1,50 $
Zemākā 52 ned.
0,00 $
Beta
1,07
Apgrozībā esošās akcijas
864,00 tūkst.
Darbinieku skaits
23
Tirgus kapitalizācija
57,01 tūkst.
Vid. apjoms
210,00
Apjoms
9,00
Augstākā 52 ned.
1,50 $
Zemākā 52 ned.
0,00 $
Beta
1,07
Apgrozībā esošās akcijas
864,00 tūkst.
Darbinieku skaits
23
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
MarketBeat
·
pirms 12 minūtēm
PDD Holdings Inc. Sponsored ADR (NASDAQ:PDD) Stock Rated "Hold" by Wall Street Brokerages
Benzinga
·
pirms 13 minūtēm
Stock Market: Will S&P 500 Open Up or Down Today?
Yahoo Finance
·
pirms 1 stundas
XRP Treasury Company Evernorth Just Went Public on Nasdaq. Here's How It Could Impact the Price of XRP.
Seeking Alpha
·
pirms 18 stundām
SPYI: The Fed Raised Rates, The Gap Grew Wider And My Favorite S&P500 Income ETF Delivered
Profils
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Par “Trevena Inc”
Ģenerāldirektors-
Darbinieki23
Dibināšanas datums2007
Galvenais birojsAtlanta, Džordžija, Amerikas Savienotās Valstis
Sektors-
Tīmekļa vietnetrevena.com